Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Crystal structure of Onconase at 1.1 Å resolution--insights into substrate binding and collective motion.

Holloway DE, Singh UP, Shogen K, Acharya KR.

FEBS J. 2011 Nov;278(21):4136-49. doi: 10.1111/j.1742-4658.2011.08320.x. Epub 2011 Sep 28.

2.

Onconase responsive genes in human mesothelioma cells: implications for an RNA damaging therapeutic agent.

Altomare DA, Rybak SM, Pei J, Maizel JV, Cheung M, Testa JR, Shogen K.

BMC Cancer. 2010 Feb 5;10:34. doi: 10.1186/1471-2407-10-34.

3.

Local controlled delivery of anti-neoplastic RNAse to the brain.

Slager J, Tyler B, Shikanov A, Domb AJ, Shogen K, Sidransky D, Brem H.

Pharm Res. 2009 Aug;26(8):1838-46. doi: 10.1007/s11095-009-9893-3. Epub 2009 May 5.

4.

Effect of Onconase on double-stranded RNA in vitro.

Saxena A, Saxena SK, Shogen K.

Anticancer Res. 2009 Apr;29(4):1067-71.

5.

The cytotoxic ribonuclease onconase targets RNA interference (siRNA).

Zhao H, Ardelt B, Ardelt W, Shogen K, Darzynkiewicz Z.

Cell Cycle. 2008 Oct;7(20):3258-61. Epub 2008 Oct 25.

6.

Onconase and amphinase, the antitumor ribonucleases from Rana pipiens oocytes.

Ardelt W, Shogen K, Darzynkiewicz Z.

Curr Pharm Biotechnol. 2008 Jun;9(3):215-25. Review.

7.

Remarkable enhancement of cytotoxicity of onconase and cepharanthine when used in combination on various tumor cell lines.

Ita M, Halicka HD, Tanaka T, Kurose A, Ardelt B, Shogen K, Darzynkiewicz Z.

Cancer Biol Ther. 2008 Jul;7(7):1104-8. Epub 2008 Apr 19.

8.

Cytostatic and cytotoxic properties of Amphinase: a novel cytotoxic ribonuclease from Rana pipiens oocytes.

Ardelt B, Ardelt W, Pozarowski P, Kunicki J, Shogen K, Darzynkiewicz Z.

Cell Cycle. 2007 Dec 15;6(24):3097-102. Epub 2007 Sep 12.

9.
10.

The therapeutic mechanisms of ranpirnase-induced enhancement of radiation response on A549 human lung cancer.

Lee I, Kim DH, Sunar U, Magnitsky S, Shogen K.

In Vivo. 2007 Sep-Oct;21(5):721-8.

11.

Possible mechanisms of improved radiation response by cytotoxic RNase, Onconase, on A549 human lung cancer xenografts of nude mice.

Kim DH, Kim EJ, Kalota A, Gewirtz AM, Glickson J, Shogen K, Lee I.

Adv Exp Med Biol. 2007;599:53-9.

PMID:
17727247
12.

Onconase, an anti-tumor ribonuclease suppresses intracellular oxidative stress.

Ardelt B, Juan G, Burfeind P, Salomon T, Wu JM, Hsieh TC, Li X, Sperry R, Pozarowski P, Shogen K, Ardelt W, Darzynkiewicz Z.

Int J Oncol. 2007 Sep;31(3):663-9.

PMID:
17671695
13.

The interdependence between catalytic activity, conformational stability, and cytotoxicity of onconase.

Schulenburg C, Ardelt B, Ardelt W, Arnold U, Shogen K, Ulbrich-Hofmann R, Darzynkiewicz Z.

Cancer Biol Ther. 2007 Aug;6(8):1233-9. Epub 2007 May 11.

PMID:
17637563
14.

Enzymatic and structural characterisation of amphinase, a novel cytotoxic ribonuclease from Rana pipiens oocytes.

Singh UP, Ardelt W, Saxena SK, Holloway DE, Vidunas E, Lee HS, Saxena A, Shogen K, Acharya KR.

J Mol Biol. 2007 Aug 3;371(1):93-111. Epub 2007 May 10.

PMID:
17560606
15.

Antitumor efficacy of the cytotoxic RNase, ranpirnase, on A549 human lung cancer xenografts of nude mice.

Lee I, Kalota A, Gewirtz AM, Shogen K.

Anticancer Res. 2007 Jan-Feb;27(1A):299-307.

16.

Mild hyperthermia predisposes tumor cells to undergo apoptosis upon treatment with onconase.

Halicka HD, Ardelt B, Shogen K, Darzynkiewicz Z.

Int J Oncol. 2007 Apr;30(4):841-7.

PMID:
17332922
17.

Onconase induces caspase-independent cell death in chemoresistant neuroblastoma cells.

Michaelis M, Cinatl J, Anand P, Rothweiler F, Kotchetkov R, von Deimling A, Doerr HW, Shogen K, Cinatl J Jr.

Cancer Lett. 2007 May 18;250(1):107-16. Epub 2006 Nov 3.

PMID:
17084521
19.

Effect of ONCONASE +/- tamoxifen on ASPC-1 human pancreatic tumors in nude mice.

Lee I, Lee YH, Mikulski SM, Shogen K.

Adv Exp Med Biol. 2003;530:187-96.

PMID:
14562716
20.

Enhancement of activation-induced apoptosis of lymphocytes by the cytotoxic ribonuclease onconase (Ranpirnase).

Halicka DH, Pozarowski P, Ita M, Ardelt WJ, Mikulski SM, Shogen K, Darzynkiewicz Z.

Int J Oncol. 2002 Dec;21(6):1245-50.

PMID:
12429974
21.

Entry into cells and selective degradation of tRNAs by a cytotoxic member of the RNase A family.

Saxena SK, Sirdeshmukh R, Ardelt W, Mikulski SM, Shogen K, Youle RJ.

J Biol Chem. 2002 Apr 26;277(17):15142-6. Epub 2002 Feb 11.

22.

Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma.

Mikulski SM, Costanzi JJ, Vogelzang NJ, McCachren S, Taub RN, Chun H, Mittelman A, Panella T, Puccio C, Fine R, Shogen K.

J Clin Oncol. 2002 Jan 1;20(1):274-81.

PMID:
11773179
23.

Induction of differentiation of leukaemic (HL-60) or prostate cancer (LNCaP, JCA-1) cells potentiates apoptosis triggered by onconase.

Halicka HD, Murakami T, Papageorgio CN, Mittelman A, Mikulski SM, Shogen K, Darzynkiewicz Z.

Cell Prolif. 2000 Dec;33(6):407-17.

PMID:
11101012
24.

Enhanced cellular radiation sensitivity of androgen-independent human prostate tumor cells by onconase.

Lee I, Lee YH, Mikulski SM, Lee J, Shogen K.

Anticancer Res. 2000 Mar-Apr;20(2A):1037-40.

PMID:
10810394
25.

Tumoricidal effects of onconase on various tumors.

Lee I, Lee YH, Mikulski SM, Lee J, Covone K, Shogen K.

J Surg Oncol. 2000 Mar;73(3):164-71.

PMID:
10738271
26.

G1 arrest of U937 cells by onconase is associated with suppression of cyclin D3 expression, induction of p16INK4A, p21WAF1/CIP1 and p27KIP and decreased pRb phosphorylation.

Juan G, Ardelt B, Li X, Mikulski SM, Shogen K, Ardelt W, Mittelman A, Darzynkiewicz Z.

Leukemia. 1998 Aug;12(8):1241-8.

PMID:
9697879
27.

Potentiation of tumor necrosis factor induced apoptosis by onconase.

Deptala A, Halicka HD, Ardelt B, Ardelt W, Mikulski SM, Shogen K, Darzynkiewicz Z.

Int J Oncol. 1998 Jul;13(1):11-6.

PMID:
9625797
28.

Inhibition of HIV-1 production and selective degradation of viral RNA by an amphibian ribonuclease.

Saxena SK, Gravell M, Wu YN, Mikulski SM, Shogen K, Ardelt W, Youle RJ.

J Biol Chem. 1996 Aug 23;271(34):20783-8.

29.

Relationship between response rate and median survival in patients with advanced nonsmall cell lung-cancer - comparison of onconase(r) with other anticancer agents.

Mikulski S, Chun H, Mittelman A, Panella T, Puccio C, Shogen K, Costanzi J.

Int J Oncol. 1995 Apr;6(4):889-97.

PMID:
21556617
30.

RNase inhibition of human immunodeficiency virus infection of H9 cells.

Youle RJ, Wu YN, Mikulski SM, Shogen K, Hamilton RS, Newton D, D'Alessio G, Gravell M.

Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):6012-6.

31.

Toxicity of an antitumor ribonuclease to Purkinje neurons.

Newton DL, Walbridge S, Mikulski SM, Ardelt W, Shogen K, Ackerman SJ, Rybak SM, Youle RJ.

J Neurosci. 1994 Feb;14(2):538-44.

32.
35.

Comparative molecular modeling and crystallization of P-30 protein: a novel antitumor protein of Rana pipiens oocytes and early embryos.

Mosimann SC, Johns KL, Ardelt W, Mikulski SM, Shogen K, James MN.

Proteins. 1992 Nov;14(3):392-400.

PMID:
1438177
37.

MR imaging of Sjögren syndrome: correlation with sialography and pathology.

Takashima S, Takeuchi N, Morimoto S, Tomiyama N, Ikezoe J, Shogen K, Kozuka T, Okumura T.

J Comput Assist Tomogr. 1991 May-Jun;15(3):393-400.

PMID:
2026798
38.

Carcinoma of the esophagus: CT vs MR imaging in determining resectability.

Takashima S, Takeuchi N, Shiozaki H, Kobayashi K, Morimoto S, Ikezoe J, Tomiyama N, Harada K, Shogen K, Kozuka T.

AJR Am J Roentgenol. 1991 Feb;156(2):297-302.

PMID:
1898802
39.
40.
41.

Striking increase of survival of mice bearing M109 Madison carcinoma treated with a novel protein from amphibian embryos.

Mikulski SM, Ardelt W, Shogen K, Bernstein EH, Menduke H.

J Natl Cancer Inst. 1990 Jan 17;82(2):151-3. No abstract available.

PMID:
2294226
42.

Cytostatic and cytotoxic effects of Pannon (P-30 Protein), a novel anticancer agent.

Darzynkiewicz Z, Carter SP, Mikulski SM, Ardelt WJ, Shogen K.

Cell Tissue Kinet. 1988 May;21(3):169-82.

PMID:
3224365

Supplemental Content

Loading ...
Support Center